The first 60 days: Indolent and smouldering systemic mastocytosis
Indolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023. Below, week by week, is what OnCo's record of Indolent and smouldering systemic mastocytosis says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis, Monitoring.
- RadiologistNamed in the standard of care for: Diagnosis.
- Medical oncologistNamed in the standard of care for: Symptom control, Moderate to severe symptoms despite supportive care, Trials.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Symptom control.
- Palliative and supportive care teamNamed in the standard of care for: Symptom control.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.
Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.
Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.
Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Serum tryptase, KIT D816V by high-sensitivity PCR in blood, Marrow mast cell aggregates with CD25, CD2 and CD30 expression, B findingsdefining smouldering disease, SRSF2, ASXL1 and RUNX1 mutations), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Indolent systemic mastocytosis with skin involvement, Indolent systemic mastocytosis without skin involvement, Bone marrow mastocytosis.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis
- For my situation (diagnosis), which of the standard options do you recommend and why?Guideline options include: Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.
Symptom control
- For my situation (symptom control), which of the standard options do you recommend and why?Guideline options include: H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.
Moderate to severe symptoms despite supportive care
- For my situation (moderate to severe symptoms despite supportive care), which of the standard options do you recommend and why?Guideline options include: Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.
- Am I a candidate for Avapritinib, Cladribine, Interferon alfa-2a/2b, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Trials
- For my situation (trials), which of the standard options do you recommend and why?Guideline options include: Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.
- Am I a candidate for Elenestinib, Bezuclastinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis and (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Monitoring
- For my situation (monitoring), which of the standard options do you recommend and why?Guideline options include: Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.
Any stage
- Are there clinical trials I could join, for example of Avapritinib, Elenestinib, Bezuclastinib, (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Whether avapritinib alters the long-term course or only symptoms is unknown”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Anaphylaxis remains life-threatening and unpredictable”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisPhase 2/3 · recruiting · NCT04910685A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo Phase 2 · active · NCT03731260A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisPhase 2 · active · NCT05186753A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Indolent and smouldering systemic mastocytosis: the full pageIndolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Molecular response (MMR, MR4, treatment-free remission): In chronic myeloid leukaemia, how far the leukaemia gene signal in the blood has fallen, measured in logs: a 1,000-fold drop is a major molecular response, a 10,000-fold drop (MR4) is 'deep'.
- Driver mutation: One of the few mutations in a tumour that actually causes it to grow.
Every term links to the glossary.